ERBB2 and breast carcinoma: In the neoadjuvant setting, the prognostic significance of CTCs detected by CellSearch was evaluated in the GeparQuattro trial in patients with operable or locally advanced HER2+ breast cancer, both before and after neoadjuvant therapy with HER2-targeted therapy together with anthracycline-taxane-based chemotherapy.